Dialysis heavyweights punch well in second quarter
This article was originally published in Clinica
Edwards Lifesciences says net sales increased by 4%, excluding the effect of foreign exchange and divested businesses. In the company's cardiac surgery division, sales were $85 million, up 10%. Growth continues to be led by robust sales of its pericardial tissue valve products. Critical care sales rose 7% to $54 million. Edwards says it is benefiting from the continued trend of customers to more advanced technology catheter products. Vascular sales fell 3% to $13 million. The company says it is on track to re-enter the European market with its Lifepath AAA Endovascular graft system, as well as resuming US clinical trials of the product, by the end of the year. Edwards voluntarily halted European sales and US clinical trials of the device after it found a fracture in the product's wireform in April 2000 (see Clinica No 906, p 1). Edwards expects a 20% increase in net income for the full year.
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.